Previous studies have shown that low‐dose antitumour angiogenic drugs can promote vascular normalization,31, 32 improved the tumour microenvironment and sensitized radiotherapy,33 Other studies have shown that anlotinib can increase T cell activity and infiltration by downregulating the expression of PD‐L1 in endothelial cells,34 which can also reshape the tumour microenvironment by increasing the infiltration of innate immune cells (Natural killer cell, T cell and B cell).35 The gene discussed is CD274; the disease is neoplasm.